NEW YORK (GenomeWeb) – Integrated Diagnostics said this week that it has obtained $47.25 million in funding, $30.25 million from the closing of its Series B round and $17 million in non-dilutive debt financing from Life Sciences Alternative Funding.

The proceeds will be used primarily for commercialization of Indi's proteomic lung cancer test, Xpresys Lung, supporting an expansion of the company's sales staff and clinical infrastructure as well as efforts to obtain reimbursement for the test, Indi CEO Albert Luderer told ProteoMonitor.